ANTIMICROBIALS: Edited by Monica A. Slavin and William IrvingImmunotherapy: a potential adjunctive treatment for fungal infectionKullberg, Bart-Jan; van de Veerdonk, Frank; Netea, Mihai G.Author Information Department of Medicine Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, Netherlands Correspondence to Bart-Jan Kullberg, Department of Medicine, Radboud University Medical Center, AIG-463, PO Box 9100, 6500 HB Nijmegen, Netherlands. Tel: +31 24 3668015; e-mail: email@example.com Current Opinion in Infectious Diseases: December 2014 - Volume 27 - Issue 6 - p 511-516 doi: 10.1097/QCO.0000000000000105 Buy Metrics Abstract Purpose of review Invasive and mucosal candidiasis are associated with major morbidity in patients with inappropriate host defence mechanisms. This review focuses on recent studies elucidating the immune response against candidiasis and possible immunotherapeutic approaches. Recent findings The last year has seen substantial advances in understanding antifungal immunity. The role of pattern recognition receptors and the Th1 and Th17 immune pathways has been further elucidated. The first genome-wide studies have identified new risk factors for candidaemia. Trials of adjuvant immunotherapy for fungal infections have provided directions for the future. Summary Understanding the fungal pathogenesis and the induction of protective antifungal adaptive immunity has advanced the development of immunotherapeutic strategies and vaccines against invasive and mucosal candidiasis. © 2014 Lippincott Williams & Wilkins, Inc.